Clinical-stage biopharmaceutical company Iambic Therapeutics, Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission on September 21, 2026, initiating its initial public offering to list its common stock on the Nasdaq Global Select Market under the ticker symbol IAM. The offering is led by underwriters J.P. Morgan, BofA Securities, and Jefferies, representing a major public milestone for artificial intelligence-driven therapeutics development.
The initial registration includes a preliminary placeholder offering amount of $100.0 million set forth in the SEC filing fee exhibit pursuant to Rule 457(o). As standard in early-stage registration filings, this dollar figure serves exclusively to calculate registration fees and does not reflect final share pricing, total share count, or ultimate capital proceeds. Readers navigating how an IPO actually works should note that pricing terms, gross primary proceeds, and potential secondary share sales remain subject to subsequent amendments before bookbuilding commences.
Key Takeaways
- Nasdaq Listing Application: Iambic filed its Form S-1 on September 21, 2026, proposing to list common stock on the Nasdaq Global Select Market under ticker IAM with J.P. Morgan, BofA Securities, and Jefferies as lead underwriters.
- Liquidity and Financial Runway: As of June 30, 2026, Iambic reported $207.88 million in cash and cash equivalents alongside $174.77 million in working capital, against an accumulated deficit of $245.30 million.
- Revenue Growth and Spending: Six-month collaboration revenue reached $12.75 million through June 30, 2026, up from $3.93 million in the prior-year period, alongside research and development expenses of $57.15 million and a net loss of $50.12 million.
- High-Profile Backing: Prominent pre-IPO stockholders include NVIDIA Corporation (9.61 million shares), Coatue Ventures II LP (9.45 million shares), Nexus Ventures V Ltd. (17.02 million shares), Q Healthcare Holding LLC (9.82 million shares), and Catalio Capital Management affiliates (18.16 million shares).
Financial Performance and Balance Sheet Structure
According to the unaudited interim financial statements in the filing, Iambic generated $12.75 million in collaboration revenue for the six months ended June 30, 2026, compared to $3.93 million for the six months ended June 30, 2025. For the full year ended December 31, 2025, collaboration revenue stood at $9.43 million.
Operating expenditures have expanded as Iambic progresses internal assets through clinical testing. Research and development expenses rose to $57.15 million during the first half of 2026, up from $32.93 million in the first half of 2025. General and administrative expenses totaled $9.12 million, resulting in total operating expenses of $66.26 million. After accounting for $3.40 million in net interest and other income, Iambic recorded a net loss of $50.12 million for the first six months of 2026, compared with a net loss of $33.17 million in the prior-year period.
| Financial Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Year Ended Dec 31, 2025 |
|---|---|---|---|
| Collaboration Revenue | $3,928 | $12,753 | $9,426 |
| Research & Development | $32,934 | $57,149 | $77,528 |
| General & Administrative | $6,669 | $9,115 | $14,248 |
| Total Operating Expenses | $39,603 | $66,264 | $91,776 |
| Net Loss | $(33,165) | $(50,116) | $(77,295) |
| Cash & Cash Equivalents | — | $207,878 | $182,752 |
On the capitalization front, Iambic had 23,605,655 shares of common stock issued and outstanding as of June 30, 2026, alongside 150,004,272 shares of convertible preferred stock carrying a balance-sheet value of $394.04 million. Upon the closing of the offering, all outstanding convertible preferred shares are slated to convert automatically into common stock on a one-for-one basis.
Clinical Pipeline and AI Platform Architecture
Iambic operates a drug discovery platform termed molecular superintelligence, which combines physics-informed machine learning models with automated high-throughput wet laboratory experiments. Its core computational infrastructure includes Enchant, a multimodal predictive AI architecture evaluating preclinical pharmacokinetic properties, and NeuralPLexer, a generative structural model mapping dynamic protein-ligand interactions.
The company’s wholly owned pipeline is led by IAM1363, a selective, brain-penetrant small molecule inhibitor of HER2. As of September 2026, IAM1363 is undergoing Phase 1/1b clinical trials in patients with HER2-altered solid tumors. Behind its lead asset, Iambic is advancing two preclinical oncology programs: IAM217, a KIF18A inhibitor, and IAM-C1, a dual CDK2/4 inhibitor. The company plans to submit Investigational New Drug (IND) applications for both IAM217 and IAM-C1 to the U.S. FDA in the fourth quarter of 2026.
Complementing its internal pipeline, Iambic maintains multi-target commercial partnerships. In February 2026, the company entered into a research collaboration and license agreement with Takeda, alongside a technology enablement agreement granting Takeda access to NeuralPLexer. Iambic also maintains an active discovery pact with H. Lundbeck A/S, providing upfront funding, research cost reimbursements, and potential development milestone fees.
Institutional Ownership and Governance
The registration filing highlights substantial participation from major technology and venture capital institutions. Prior to the offering, 5% or greater beneficial stockholders include:
- Entities affiliated with Catalio Capital Management: 18,163,772 shares (across Catalio Nexus Fund III and Catalio Access Fund VIII).
- Nexus Ventures V Ltd.: 17,023,474 shares.
- Q Healthcare Holding LLC (Qatar Investment Authority): 9,817,255 shares.
- NVIDIA Corporation: 9,611,286 shares.
- Coatue Ventures II LP: 9,445,874 shares.
Executive leadership also holds significant equity. Co-founder and Chief Executive Officer Thomas Miller, Ph.D., beneficially owns 7,330,249 shares, while Co-founder and Chief Technology Officer Frederick Manby, Ph.D., holds 10,330,248 shares. In total, all executive officers and directors as a group hold 44,297,408 shares of capital stock prior to the offering.
Capital Markets Context and What to Watch Next
The filing arrives during a selective window for biopharma equity issuance. Understanding how IPOs shape the equity capital market reveals that public market investors increasingly favor platform biotechs that possess both proprietary computational data moats and validated clinical-stage assets.
Key upcoming catalysts for Iambic include:
- Form S-1/A Terms: Subsequent amendments establishing the exact share count, proposed price range, and net proceeds target.
- Regulatory IND Filings: Planned fourth-quarter 2026 submissions for IAM217 and IAM-C1 to initiate Phase 1/2 clinical testing.
- Clinical Data Milestones: Ongoing dose escalation and preliminary efficacy findings from the IAM1363 Phase 1/1b trial in HER2-mutated and amplified cancers.
Sources
- U.S. Securities and Exchange Commission: Form S-1 Registration Statement of Iambic Therapeutics, Inc. (CIK 0001997038), filed September 21, 2026.
- U.S. Securities and Exchange Commission: Form S-1 Filing Fee Exhibit for Iambic Therapeutics, Inc., filed September 21, 2026.
Disclosure: This article is for informational purposes only and is not investment advice.